Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Neoplasm Proteins
  • Neovascularization, Physiologic
  • Polymorphism, Single Nucleotide
  • Pyrimidines
  • Receptor Protein-Tyrosine Kinases
  • Sulfonamides

abstract

  • Germline variants in angiogenesis- and exposure-related genes may predict treatment response to pazopanib monotherapy in patients with RCC. If validated, these markers may explain why certain patients fail antiangiogenesis therapy and they may support the use of alternative strategies to circumvent this issue.

publication date

  • June 20, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.9110

PubMed ID

  • 21576632

Additional Document Info

start page

  • 2557

end page

  • 64

volume

  • 29

number

  • 18